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Obesity-induced insulin resistance and type 2 diabetes mellitus can ultimately result in various 
complications, including diabetic cardiomyopathy. In this case, cardiac dysfunction is characterized by 
metabolic disturbances such as impaired glucose oxidation and an increased reliance on fatty acid 
oxidation. Mitochondrial dysfunction has often been associated with the altered metabolic function in 
the diabetic heart, and may result from fatty acid-induced lipotoxicity and uncoupling of oxidative 
phosphorylation. In this review, we address the metabolic changes in the diabetic heart, focusing on the 
loss of metabolic flexibility and cardiac mitochondrial function. We consider the alterations observed in 
mitochondrial substrate utilization, bioenergetics and dynamics, and highlight new areas of research 
which may improve our understanding of the cause and effect of cardiac mitochondrial dysfunction in 
diabetes. Finally, we explore how lifestyle (nutrition and exercise) and pharmacological interventions 
can prevent and treat metabolic and mitochondrial dysfunction in diabetes. 
Keywords: diabetes, heart, lipotoxicity, mitochondria 
Abbreviations: 
Akt, protein kinase b; ANT, adenine nucleotide translocase; cGMP, cyclic guanosine monophosphate; CK, 
creatine kinase; CPT1, carnitine palmitoyltransferase 1; CR, caloric restriction; CS, citrate synthase; DAG, 
diacylglycerol; eNOS endothelial nitric oxide synthase; ETS, electron transfer system; FA, fatty acid; FAO, 
fatty acid oxidation; GLUT4, glucose transporter 4; HIIT, high intensity interval training; IRS-1, insulin 
receptor substrate 1; JNK, C-Jun-N-terminal kinase; MCD, malonyl-CoA decarboxylase; MCU, 
mitochondrial calcium uniporter; MICU1, mitochondrial calcium uptake protein 1; MIT, moderate 
intensity training; MVO2, myocardial oxygen consumption; NCLX, Na+/Ca2+ exchange; NF-κB, nuclear 
factor kappa-light-chain enhancer of activated B-cells; NLRP3, nucleotide-binding domain, leucine-rich–
containing family, pyrin domain–containing-3; NO, nitric oxide; OXPHOS, oxidative phosphorylation; PCr, 
phosphocreatine; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1α; PKC, 
protein kinase C; PPAR, peroxisome proliferator-activated receptor; PVA, pressure-volume area; ROS, 
reactive oxygen species; SGLT, sodium-glucose cotransporter; Sirt, sirtuin; T2DM, Type 2 Diabetes 
Mellitus; TLR, toll-like receptor; UCP, uncoupling protein. 
  

































































Type 2 diabetes mellitus (T2DM) has reached epidemic proportions; in 2014 around 422 million people 
had been diagnosed with T2DM, corresponding to about 8.5% of the global population of adults over 18 
years of age 1. Obesity is a major risk factor for the development of T2DM, leading to an increased risk 
of cardiovascular disease, particularly coronary artery disease and stroke. Diabetic cardiomyopathy was 
first described in 1972 2, and since then, large cohort studies, such as the Framingham study 3 and the 
Strong Heart Study 4 have reported left ventricular hypertrophy in patients with T2DM, independent of 
hypertension. More recently, diabetic cardiomyopathy was described as a restrictive phenotype with 
concentric LV remodelling and diastolic LV dysfunction. These two phenotypes are not considered to be 
successive stages of diabetic cardiomyopathy, but instead each evolves independently to, respectively, 
heart failure with preserved left ventricular ejection fraction (HFPEF) or reduced left ventricular ejection 
fraction (HFREF)5. 
Individuals with pre-diabetes and patients with uncomplicated T2DM often suffer from circulating 
hyperglycemia, hypertriglyceridemia and elevated plasma levels of non-esterified fatty acids (FAs). This 
increased FA availability leads to increased myocardial FA uptake and further reduces insulin-mediated 
glucose uptake, shifting cardiac ATP production almost exclusively towards FA oxidation (FAO) 6 both in 
early 7 and late diabetes 8,9. Mouse studies suggest that the altered substrate preference precedes the 
development of cardiac dysfunction 10, implicating altered cardiac metabolism in the development of 
diabetic cardiomyopathy. Moreover, despite this relative increase in FAO, the excess supply of FAs 
results in the accumulation of lipid intermediates, which in turn play a major role in the pathophysiology 
of diabetic cardiomyopathy. 
Here we initially consider these metabolic adaptations in the obese, insulin-resistant and ultimately type 
2 diabetic heart, focusing on the loss of metabolic flexibility. We subsequently review the lipotoxicity-
induced alterations in cellular and mitochondrial bioenergetic function of the diabetic heart. Finally, we 
explore how metabolic and mitochondrial alterations can be prevented by lifestyle and/or 
pharmacological intervention.  
 
































































2. PATHOPHYSIOLOGY OF DISTURBANCES IN MITOCHONDRIAL METABOLISM IN 
T2DM 
2.1. Metabolic inflexibility and myocardial substrate utilization  
To maintain its high energy demand, the heart utilizes multiple energy-providing substrates, primarily 
triglycerides, non-esterified FAs, carbohydrates (glucose and lactate), and to some extent also ketone 
bodies and amino acids. The contribution of these individual substrates to ATP production depends on 
substrate availability, hormonal status and energy demand, and the capacity of the normal heart to 
switch between the different energy substrates is referred to as “metabolic flexibility”. With the 
development of insulin resistance, however, the metabolic flexibility of the heart (as well as skeletal 
muscle) deteriorates, such that myocardial energy production becomes primarily dependent on FAO. 
This concept is coined metabolic inflexibility or loss of metabolic flexibility11. In the 1960s, Sir Philip 
Randle performed landmark studies showing how products of increased FAO can inhibit glucose uptake 
in muscle 12. This mechanism, subsequently known as the Randle Cycle, underpins the "metabolic 
flexibility" of healthy individuals, i.e. the capacity to switch between fuels, depending on nutrient 
composition and intake, as well as variations in insulin signalling. Cardiac metabolic flexibility is also 
linked to daily fasting-feeding cycles and the cellular circadian rhythm, which coordinate a vital interplay 
between food intake and metabolism. Recent data from humans and animal models suggest that 
disturbances in feeding and the circadian rhythm, e.g. as a result of jet-lag or shift-work, could lead to 
the development of insulin resistance 13-16 (see also section 4.2). 
With the development of insulin resistance, however, the metabolic flexibility of the heart (as well as 
skeletal muscle) deteriorates, such that myocardial energy production becomes primarily dependent on 
FAO. The heart can use other substrates as metabolic fuel, such as branched-chain amino acids and 
ketone bodies, however the relative contribution of these substrates to total ATP production is relatively 
low, and little is currently understood about their importance in insulin resistance and T2DM. The high 
supply of FAs exceeds mitochondrial FAO capacity, resulting in the accumulation of intermediates of FA 
metabolism in the cardiomyocytes and causing a state of lipotoxicity 17. Lipotoxicity can lead to cellular 
oxidative stress, impaired cytosolic and mitochondrial calcium homeostasis and mitochondrial 
dysfunction.  
































































Diabetic cardiomyopathy is therefore initially characterized by metabolic disturbances and diastolic 
dysfunction (left ventricular stiffness and impaired relaxation) 10,18,19. This condition can ultimately 
progress to cardiac hypertrophy and/or systolic dysfunction when lipotoxicity and/or local perfusion 
heterogeneities result in cell death and fibrosis 3,6,7,20.   
2.2. Increased myocardial oxygen consumption and impaired energetics 
Landmark studies in the 1970s 21 reported that canine myocardial oxygen consumption (MVO2) increased 
markedly in response to acute elevations in the plasma concentration of FAs. Increased FA utilization 
and increased MVO2 have also reported in obese women with insulin resistance 22. The cellular and 
molecular mechanisms behind these metabolic alterations are not clear, although it has been suggested 
that uncoupling of oxidative phosphorylation (OXPHOS) and induction of energy-wasting triglyceride-FA 
23,24 and Ca2+ cycling 25 could contribute to this elevation in MVO2. It was proposed that excess substrate 
supply might result in impaired transcriptional regulation of proteins constituting the pathways of 
cardiac energy metabolism 26. Indeed, in patients undergoing coronary artery bypass graft surgery, 
elevated plasma FA concentrations were associated with increased expression of cardiac mitochondrial 
uncoupling proteins (UCPs) 27. Moreover, an impaired cardiac energy reserve in patients with T2DM (as 
indicated by a lower myocardial phosphocreatine (PCr)/ATP ratio) correlated with fasting plasma FA 
concentration 28, a finding which could also be explained by increased uncoupling of OXPHOS. Cardiac 
PCr/ATP ratios have also been found to be reduced during catecholamine stress 29 or exercise 30 in people 
with obesity and insulin resistance, although another study failed to confirm this latter observation 6. 
Whether a lower myocardial PCr/ATP ratio in diabetic cardiomyopathy is a cause or effect of the 
progression to heart failure is currently unknown 31.  
2.3. Cardiac efficiency 
Cardiac efficiency is characterized by the relationship between the mechanical performance and energy  
consumption of the heart, whether measured as ATP utilization or oxygen consumption. Introduction of 
the conductance catheter allowed calculation of the total work performed by the heart during the 
cardiac cycle as pressure-volume area (PVA), and the relationship between MVO2 and PVA allowed 
calculation of the oxygen used for mechanical activity vs. oxygen consumption used for basal metabolism 
































































and excitation-contraction coupling (unloaded MVO2) 32. Around the turn of the 21st century, Korvald et 
al. 33 showed, for the first time, that the MVO2-PVA relationship was significantly influenced by changes 
in myocardial substrate metabolism in pigs. Thus, a change in myocardial metabolism from glucose 
towards FAO shifted the in vivo MVO2-PVA relationship upward in a parallel manner, indicating 
decreased cardiac efficiency, which could be ascribed to a higher unloaded MVO2 (i.e. more oxygen used 
for basal metabolism and excitation-contraction coupling in the case of FAO). Similar observations were 
reported by How et al. 34 using isolated perfused working mouse hearts exposed to different workloads. 
Here, elevating FA concentration in the perfusion buffer shifted the MVO2-PVA relationship upward, 
resulting in a near 30% increase in unloaded oxygen cost (Figure 1).  
 
Fig. 1: Relationship between myocardial oxygen consumption (MVO2) and total cardiac work (measured 
as pressure volume area, PVA) in a mouse heart perfused with low (0.3 mmol/L, filled circles) and high 
(0.9 mmol/L, open circles) FA concentration. Extrapolation of the regression lines to zero work allows the 
myocardial oxygen cost to be separated in two independent parts: unloaded MVO2 (reflecting oxygen 
cost for excitation-contraction coupling and basal metabolism) and excess MVO2 (reflecting the amount 
of oxygen that is converted to mechanical work 34. 

































































Finally, hearts from the diabetic db/db mouse show metabolic shifts towards a predominant FA 
utilization, and the MVO2-PVA relationships obtained from these hearts were also shifted upward 
relative to those of normal mouse hearts 35. These results therefore demonstrate that acute elevations 
in myocardial FAO, but also more chronic dependence on FA as oxidative fuel for the heart such as in 
T2DM, results in decreased cardiac efficiency. It should be noted that the FA-induced elevation in MVO2 
can by no means be explained by the switch in metabolism from glucose to FA, since the differences in 
phosphorylation–to-oxidation (P/O) ratios between FA and glucose oxidation (2.33 vs 2.58, respectively) 
could account for a maximum increase in oxygen consumption of 11%. Other mechanisms, e.g. 
uncoupling of oxidative phosphorylation and induction of futile cycles, as discussed in section 2.2 above, 
could explain the high MVO2 during predominant FA utilization. 
In conclusion, the healthy heart is characterized by a high metabolic flexibility, whereby metabolic supply 
and demand are optimally matched. The cardiac muscle from patients with insulin-resistance and 
diabetes cannot effectively switch from FA to glucose metabolism in the postprandial state and are 
therefore metabolically less flexible in adapting fuel preference to altered energy supply and demand. 
When relying primarily on FAO for energy production, the heart uses more oxygen for a given workload, 
compared with a heart oxidizing a mixture of FA and glucose. The FA-induced elevation in MVO2 is due 
to increased oxygen use for non-contractile processes, such as basal metabolism and excitation-
contraction coupling. 
2.4. Fatty acid metabolism and cellular lipotoxicity 
Lipid metabolism is a complex process, involving lipid intake, synthesis, transport and metabolism. FAs 
are major components of all lipid species, and thus the lipid content of plasma and tissues depends upon 
FA availability. FAs also influence multiple intracellular processes through mechanisms that include the 
activation of peroxisome proliferator-activated receptor (PPAR)α and PPAR gamma coactivator 1 α (PGC-
1α), leading to the upregulation of genes involved in FA metabolism and the biogenesis of peroxisomes 
and mitochondria. Reports have suggested that excessive FAs might augment inflammation through 
activation of toll-like receptor (TLR) signaling and following activation of nuclear factor kappa-light-chain 
































































enhancer of activated B-cells (NF-κB) 36. There is increasing evidence that FA availability is an 
independent predictor of metabolic disorders including insulin resistance and T2DM 37-40. It appears 
likely that FA accumulation results in increased levels of FA intermediates, such as long-chain 
acylcarnitines, which underpin lipotoxic effects in heart mitochondria 41. Notably, however, in contrast 
to saturated long-chain FAs, polyunsaturated FAs at reasonable amounts are cardioprotective rather 
than detrimental to the heart and mitochondrial function 42.  
2.4.1. Fatty acid-induced uncoupling of oxidative phosphorylation  
It has been proposed that FA-induced mitochondrial uncoupling contributes to the higher MVO2 and 
impaired ATP synthesis capacity in the T2DM heart43. Indeed, the higher leak respiration and lower 
ADP/O ratio observed in mitochondria isolated from hearts of ob/ob mice suggest that mild 
mitochondrial uncoupling is one of the causes for the reduced OXPHOS capacity 43,44. Proton leak across 
the inner mitochondrial membrane, mediated by proteins such as the adenine nucleotide translocase 
(ANT) and UCPs have been proposed to increase the respiratory rate and decrease the proton 
electrochemical gradient. This would significantly affect the cellular metabolic rate in various cell types 
45, with consequent impairment of ATP synthesis. Cardiac UCP3 expression has been shown to be 
regulated primarily by PPARα, whilst cardiac UCP2 expression is regulated in part by a FA-dependent, 
PPARα-independent mechanism 46,47. Increased expression of UCP3 has been described in the hearts of 
animals with streptozotocin-induced diabetes 48. Other studies have demonstrated an association with 
UCP3 and enhanced myocardial FAO during insulin resistance diabetes and diabetes 49-51, and in humans 
increased concentrations of circulating free FAs correlate with expression of both UCP2 and UCP3 27. 
However, FA-induced leak respiration can occur without alterations in UCP3 protein content (e.g. as in 
ob/ob hearts 43,52). This suggests a role for other mechanisms that may also mediate proton leak, 
independent of uncoupling proteins. Notably, recent observations suggest that mitochondrial ADP/ATP 
carriers, also activated by FA 53, may be responsible for FA-induced increase in leak respiration.  
There does not seem to be a role for UCP3 as a mechanism to transport FA out of the mitochondria 
during elevated FA supply 54, as has been suggested previously 55. However, enhanced UCP3 expression 
has been associated with the mitigation of oxidative stress 56, and in line with this there is evidence to 
suggest a relationship between increased mitochondrial ROS and UCP3 deficiency 52,57,58. In intact cell 
































































systems, mild mitochondrial uncoupling, due to a decrease in ∆Ψm, has been proposed to be a protective 
strategy under conditions of oxidative stress such as diabetes and obesity 50,59. However, this situation 
may only apply at the extremes of high redox potential, which is further elaborated within the R-ORB 
hypothesis (Redox-Optimized ROS Balance)60.  
The debate regarding the capacity of UCPs to uncouple mitochondria in the heart 53,61 and the extent to 
which UCP3 is involved in the prevention of ROS formation 60,62,63 remains unsettled. However, the 
correlation between UCP3 levels and FAO in the heart under obese/diabetic conditions does support a 
role for UCP3 under conditions of perturbed cardiac energy balance 64. In line with this, UCPs and the 
mechanistic basis of mitochondrial uncoupling in the obese and T2DM heart remains an area that 
requires further study. 
 
2.4.2. Long-chain acylcarnitine-induced lipotoxicity 
Several steps are needed to ensure long-chain FA transport into the mitochondria. The first step of long-
chain FA metabolism is the synthesis of long-chain acyl-CoA in the outer mitochondrial membrane 
catalysed by acyl-CoA synthase 65. Next, the synthesis of long-chain acylcarnitine is catalysed by carnitine 
palmitoyltransferase I (CPT1) to allow FA to cross the mitochondrial inner membrane 66. Long-chain FAO 
rate is therefore regulated by the cytosolic concentration of malonyl-CoA, which is an allosteric inhibitor 
of CPT1 67. Activation of insulin signaling stimulates malonyl-CoA synthesis and inhibits CPT1 68, providing 
an important mechanism for the regulation of FAO and adaptation of cardiac metabolism to substrate 
availability and nutritional state. 
The shift towards long-chain acylcarnitine accumulation is a result of unbalanced acylcarnitine synthesis 
and mitochondrial oxidation rates, which leads to accumulation of long-chain acylcarnitines in 
mitochondria – often referred to in the literature as incomplete FAO 69. In this case, the highest 
concentrations of long-chain acylcarnitines are found in the mitochondrial inner membrane and the 
intermembrane space 70, but long-chain acylcarnitines can also escape from mitochondria and inhibit 
the insulin signaling cascade upstream of protein kinase b (Akt) phosphorylation 71,72, favouring FA 
metabolism at the expense of glucose/pyruvate metabolism 73. Meanwhile, in cardiac mitochondria, 
































































long-chain acylcarnitines inhibit pyruvate and lactate metabolism even at physiological concentrations 
73. At elevated levels, the accumulation of long-chain acylcarnitines inhibits OXPHOS, inducing 
mitochondrial membrane hyperpolarization and stimulating ROS production 70,74. Thus, in patients with 
insulin resistance and T2DM, the high mitochondrial content of long-chain acylcarnitines could increase 
the risk of mitochondrial and cardiac damage, particularly in conditions of cardiac ischemia, whilst mild 
uncoupling of mitochondria might prove to be a useful strategy. Interestingly, the accumulation of long-
chain acylcarnitines per se and altered PI3K signalling likely have additional, less studied, consequences 
for cardiomyocyte function, namely electrophysiological alterations, predisposing the cardiomyocytes 
to cellular arrhythmias 75,76. This may help to explain why patients with T2DM also have an increased risk 
of life-threatening arrhythmias. Overall long-chain acylcarnitines are physiologically important 
substrates for energy metabolism during the fasted state, however, their accumulation in insulin-
resistant subjects might result in disturbances of energy metabolism and elevated risk of cardiac 
damage. 
2.4.3. Diacylglycerol- and ceramide-induced lipotoxicity 
Other lipid metabolism intermediates, namely diacylglycerols (DAG) and ceramides, have been shown 
to interact with the insulin signaling pathway (Figure 2) and their accumulation might lead to metabolic 
disturbances. The accumulation of DAGs increases protein kinase C (PKC)-θ and PKC-ε translocation in 
heart, following the reduction of Akt phosphorylation and decreased expression of mitochondrial fusion 
mediators 77. Ceramides inhibit Akt signaling via increased protein phosphatase 2 activity 78,79 and 
activation of atypical PKC-ζ 80,81. In addition, in isolated rat heart mitochondria, ceramides perturb 
mitochondrial membrane structure, inhibit mitochondrial complex I and III, and increase ROS production 
82-84.  
The relative contribution of these lipid intermediates to insulin resistance and altered mitochondrial 
function remains to be elucidated, and in particular it is not clear whether lipid intermediates accumulate 
in cardiac tissues at sufficient levels to induce insulin resistance and alter mitochondrial function. It was 
recently reported, however, that the diabetic heart exhibits a decreased mitochondrial capacity for β-
oxidation and increased accumulation of intracellular lipids, even in the absence of contractile failure 85. 
Depending on nutritional status and metabolic state, concentrations of lipid intermediates vary 
significantly. The DAG content in control animal hearts varies from 50 to 800 nmol/g 86,87.  Genetic 
































































manipulation, diabetes, and chronic lipid overload might increase cardiac DAG content several fold 86-88, 
however when manipulating lipid content and signalling pathways by dietary, genetic or pharmacological 
means, it is not possible to influence the content of a single lipid intermediate in isolation of other 
upstream or downstream intermediates. This has lead to controversial observations in vitro in various 
animal and human studies 89. For example, myriocin, a pharmacological tool used to limit ceramide 
accumulation-induced insulin resistance, has been shown to alter energy balance, weight gain, and 
ectopic lipid accumulation in multiple models of obesity 90. Very recently however, it has been suggested 
that highly insulin-sensitive, endurance-trained athletes have elevated intramuscular lipid contents 
(triglycerides, DAG and ceramides) similar to those of insulin-resistant obese and T2DM subjects (known 
as the athlete’s paradox) 91. The mechanistic basis behind this observation is currently unknown, but 
likely relates to the intrinsically high mitochondrial function (and FA flux). 
2.5. Systemic inflammation and cardiac mitochondrial function in T2DM 
Systemic low-grade inflammation has been highlighted as a possible link between obesity, insulin 
resistance and metabolic disorders in T2DM. Secretion of pro-inflammatory cytokines from obese 
adipose tissue is thought to result in dysregulation of adipocyte metabolism with increased release of 
non-esterified FAs, which over time leads to ectopic fat deposition, including in the form of epicardial 
fat. The latter contributes to a local pro-inflammatory environment of adjacent cardiomyocytes 92 with 
a substantial increase in macrophage infiltration 93. The development of inflammation in T2DM has been 
extensively reviewed 94, and here we focus on the key concepts of how a low-grade systemic 
inflammation in T2DM affects mitochondrial metabolism.  
Circulating inflammatory markers, but also non-esterified FAs and high glucose, are known to activate 
TLRs on the myocardial cell membrane (particularly TLR2 and TLR4), increasing the transcriptional 
activity of NF-κB inside cardiomyocytes 95,96. In addition, C-Jun-N-terminal kinase (JNK) activity is higher 
in cardiomyocytes of patients with obesity or T2DM than in healthy individuals, and this is probably due 
to circulating pro-inflammatory cytokines such as tumor necrosis factor -𝛼 and interleukin-6 97. The 
subsequent NF-κB-and JNK-mediated inhibition of insulin receptor substrate 1 (IRS-1) and PI3K-Akt 
results in the removal of glucose transporter 4 (GLUT4) from the plasma membrane 98. This process 
exacerbates the inhibition of cardiac glucose uptake and contributes to enhanced FAO seen in T2DM 99. 
































































Moreover, proinflammatory cytokines and caspases are produced intracellularly by the NF-κB and  JNK-
pathways. Together with long-chain saturated FAs (e.g. palmitate), ceramides, modified low-density 
lipoprotein, and glycemia (which are all elevated in T2DM), this can activate the cardiac NLRP3 
inflammasome 100, although it is uncertain whether FAs alone can also promote activation of the NLRP3 
inflammasome 101. By a currently unknown cellular process, likely involving additional factors such as 
transforming growth factor beta-1 (TGF-β1), the NLRP3 receptor binds to mitochondria, increasing ATP 
hydrolysis and ROS production 102. Meanwhile, mitochondria can also promote NLRP3 inflammasome 
activation through local ROS production, cytosolic mitophagy-induced mtDNA accumulation, and binding 
to cardiolipin 101. What the causes and consequences are of this mitochondrial binding is currently 
unknown.  
 
































































Fig. 2. In T2DM, a high supply of fatty acids (FA) from adipose tissue and circulating lipoproteins lead to 
lipid overload and a state of lipotoxicity in the cardiomyocyte, characterized by accumulation of long-
chain acyl-CoA and acylcarnitines, as well as ceramides and DAGs. In turn, these substances inhibit insulin 
receptor phosphorylation and intracellular insulin signaling, with subsequent impairment of glucose 
uptake and oxidation. This effect is reinforced by circulating pro-inflammatory cytokines. A high FA 
uptake accelerates futile triglyceride-fatty acid cycling and mitochondrial uncoupling, reducing cardiac 
efficiency. Moreover, changes in (mitochondrial) membrane lipid composition and ROS production may 
contribute to supercomplex destabilization and disturbances in fission/fusion dynamics in T2DM. Altered 
cytosolic calcium handling causes changes in mitochondrial calcium concentration, modulating 
mitochondrial enzyme activities.  
Abbreviations: β-ox, β-oxidation; Akt, protein kinase b; CPT1, carnitine palmitoyl transferase 1; DAG, di-
acylglycerol; FATP1, fatty acid transport protein 1; Glut 4, glucose transporter 4; IRS, insulin receptor 
substrate; MCU, mitochondrial calcium uniporter; PDC, pyruvate dehydrogenase complex; PI3K, 
phosphatidyl inositol 3-kinase; PKC, protein kinase C; ROS, reactive oxygen species; TCA cycle, 
tricarboxylic acid cycle; UCP, uncoupling protein 
3. MITOCHONDRIAL STRUCTURE AND FUNCTION IN THE DIABETIC HEART  
Numerous studies have suggested that lipotoxicity affects mitochondrial respiration, however, the 
altered mitochondrial metabolism in the diabetic heart cannot fully be explained by the accumulation of 
lipids and FA intermediates per se, suggesting the influence of additional factors. A variety of changes in 
cardiac mitochondrial morphology, structure and function have also been observed in insulin resistance 
and T2DM. However, there are conflicting reports of changes to mitochondrial number/content in the 
diabetic heart and it remains unclear whether mitochondria have a smaller size or are more fragmented. 
Increased mitochondrial mass, area and number were observed in hearts from diabetic mice 44,103,104 
whereas no differences in mitochondrial content were found in ob/ob mice 105 or high fat diet-induced 
diabetic mice 19. Adding to the complexity, a lower mitochondrial content was seen in the hearts of 
fructose-fed rats with T2DM, but this was not associated with a loss in respiratory capacity per 
mitochondrial mass 106. Of note, however, even if T2DM is associated with a higher cardiac mitochondrial 
































































density, this would not necessarily result in a higher OXPHOS capacity. In fact, a lower mitochondrial 
OXPHOS capacity is commonly seen in diabetes, e.g. in human atrial tissue from patients with T2DM 107 
and metabolic syndrome 108. In experimental mouse models of insulin resistance and diabetes, reduced 
cardiac function is frequently associated with lower maximal oxidative capacities compared with lean 
controls, using pyruvate, glutamate and FA substrates 19,44,52,109. The picture is not clear, however, and 
elevated FAO in the diabetic heart 105,110 has been associated with both increased 106 and decreased 
19,44,107 mitochondrial respiration in the presence of FA substrates.  
Using permeabilized cardiac fibers, Boudina and colleagues 44 found lower NADH-linked and 
palmitoylcarnitine-supported mitochondrial respiration in db/db mice. As such, the higher FAO 
measured in the isolated diabetic heart does not necessarily correspond to higher ex vivo mitochondrial 
respiration rates using FA substrates. In support of this, Wang et al 105 did not find increased maximal 
respiration with FAs in permeabilized cardiac fibers following high fat feeding of ob/ob mice.   
Activity of mitochondrial complexes I, II and IV have been reported to be low in patients with diabetes 
111 and in the hearts of insulin resistant mice 43,112. Although protein levels of mitochondrial complexes 
were reportedly unchanged in the db/db mouse heart, lower content of the α subunit of ATP synthase 
was associated with increased ROS production and oxidative stress 44. Transcriptional activity of PPARα 
and PGC-1α are reported to be upregulated in the diabetic heart, whereas, activity of pyruvate 
dehydrogenase is diminished 43,106,113. Spectrophotometric assessment of mitochondrial complex activity 
or analysis of protein levels do not provide a complete picture of mitochondrial function though, and 
instead this should ideally be assessed in functionally-intact respiring mitochondria. Moreover, in 
addition to enzymatic activities and transporter levels, OXPHOS is regulated by mitochondrial dynamics 
(fusion/fission) 114,115, cristae formation 116,117, and supercomplex organisation 118,119. Furthermore, a 
wide range of post-translational modifications of mitochondrial proteins contributes to the regulation of 
pathways responsible for mitochondrial ROS and redox conditions, as well as for substrate metabolism, 
where lysine acetylation has emerged as an important modulator of cardiac metabolism. In the diabetic 
myocardium enhanced acetylation of mitochondrial proteins has been reported to diminish complex I 
function and efficiency of ATP production 120,121, as well as NADH-linked respiration 122. Meanwhile, 
increasing evidence has highlighted how mitochondrial shape and cristae remodelling is influenced by 
































































obesity and insulin resistance 123,124, which in turn regulate mitochondrial metabolism 125. Here, we 
discuss the recent advances in these fields, with a particular focus on insulin resistance and T2DM. 
3.1. Mitochondrial fission, fusion and biogenesis 
Recent studies have highlighted a key role for altered mitochondrial quality control in diabetic 
cardiomyopathy. Mitochondria undergo structural changes in architecture through the process of fusion 
and fission dynamics. Interruption of fusion/fission has been associated with impaired mitophagy, 
contributing to the development of cardiomyopathy 126. Therefore, altered mitochondrial dynamics 
negatively affects mitochondrial respiration and increases ROS generation, however this may in turn be 
a consequence of abrogated quality control within the mitochondrial network.  
Increased mitochondrial fragmentation and the downregulation of mitochondrial fusion proteins were 
found in atrial tissue from patients with T2DM 108. Correspondingly, in a mouse model of cardiac 
lipotoxicity more fragmented mitochondria were seen and this was attributed to enhanced 
mitochondrial fission (via DRP1) and reduced fusion 124. 
The observation that nutrient overload results in mitochondrial fission is of particular interest in the 
context of T2DM 115. Although fragmentation can occur under conditions of nutrient overload, it remains 
unclear whether this is due to diet-induced oxidative stress or to specific toxic effects of high glucose 
and/or FAs 124. Proteins controlling mitochondrial dynamics are clearly sensitive to ROS 127, and in line 
with this, altering the redox state through over-expression of superoxide dismutase and/or use of a 
superoxide dismutase mimetic reduced mitochondrial fragmentation 104,107,124.  
In cardiomyocytes, insulin can acutely regulate mitochondrial metabolism through a mechanism that 
depends on increased mitochondrial fusion via Opa-1 123. Opa-1, located in the mitochondrial inner-
membrane, is a main regulator of mitochondrial fusion and participates in cristae remodelling 117. Higher 
Opa-1 levels due to increased insulin signaling were associated with higher mitochondrial membrane 
potential, ATP production, and OXPHOS capacity 123, and may also contribute to the stabilization of 
mitochondrial supercomplexes 128,129 (see section 3.2). Thus, impaired insulin signaling may also directly 
contribute to mitochondrial structural remodelling in the heart. 
Adult cardiomyocytes have a regionally interconnected mitochondrial subnetwork that is thought to 
limit the cellular consequences of mitochondrial dysfunction by disconnecting damaged mitochondria 
































































within seconds, essentially serving as a local power grid protection 130. It is conceivable that 
mitochondrial fragmentation (and the consequent lowering of mitochondrial membrane potential) may 
protect the remaining mitochondria from the damage of energy overload 115 or ROS 131. However, the 
role of mitochondrial dynamics in the diabetic heart remains to be fully explored, particularly the 
importance of dynamics in the regulation of ATP production and mitophagy.   
 
3.2. Mitochondrial supercomplex function in T2DM 
Assembly of mitochondrial protein complexes into supercomplexes is an important factor in optimizing 
OXPHOS function (Figure 3). However, the exact composition and functional role of the supercomplexes 
are still unclear 132-138. Preliminary evidence suggests that mitochondrial membrane lipid composition 
and peroxidation may influence supercomplex organization 139. In particular, cardiolipin is considered to 
be an important factor anchoring the supercomplex in the mitochondrial inner-membrane 140. 
Furthermore, cristae morphology may influence supercomplex formation and stability 128. Supercomplex 
formation can facilitate changes in OXPHOS capacity without necessarily altering the expression of 
individual protein complexes. Indeed, in the non-diabetic failing dog heart, Rosca et al. 141 reported a 
decrease in cardiac respiration rate, without any reduction in the enzymatic activity of individual 
mitochondrial complexes, whilst  formation of supercomplexes was lower and the number of isolated 
individual mitochondrial complexes increased 141. 
Limited data is available on supercomplex function and composition in the diabetic heart. In skeletal 
muscle fibres of overweight women with T2DM, a reduction in OXPHOS capacity was associated with a 
significant decrease in complex I-III-IV containing supercomplexes compared with controls 118. More 
recently, the same group reported lower OXPHOS capacity, lower supercomplex assembly and more 
oxidative damage to proteins in the atrial tissue of patients with T2DM and atrial fibrillation 119. 
Interestingly, a high-fat diet did not alter mitochondrial supercomplex formation in cardiac muscle of 
C57BL/6 mice, although remodelling of cardiolipin acyl chains was observed 142. In addition, dramatic 
loss of cardiolipin content and remodelling of acyl chains were observed in very early stages of 
streptozotocin-induced diabetes and in ob/ob mouse hearts 143. It has been proposed that lyso-
cardiolipin acyltransferase 1 (ALCAT1) is upregulated by oxidative stress and determines cardiolipin-
































































remodelling by catalyzing the synthesis of cardiolipin species that are highly sensitive to oxidative 
damage 144. It should be noted, however, that although no significant changes in mitochondrial function 
have been reported after short-time (5 days) exposure to streptozotocin 143, the remodelling of 
cardiolipin could promote alterations in mitochondrial function by destabilizing supercomplexes during 
onset of diabetes. Interestingly, some impairment of cardiolipin synthesis may be tissue-specific and 
even have a protective effect.  In Tafazzin knockout mice, there was a decrease in the cardiolipin level in 
heart and skeletal muscle, but not in liver, where higher synthesis rates preserved the cardiolipin level 
145. As a result, hypermetabolism in liver protected these animals from high-fat diet-induced weight gain 
and glucose intolerance. 
Another mitochondrial supercomplex, known as the mitochondrial interactosome (Figure 3B), is 
comprised of the mitochondrial ATP synthase, ANT, inorganic phosphate carrier, the mitochondrial 
creatine kinase (mtCK) and voltage dependent anion channel (VDAC)146,147. In the oxidative muscle cells 
the diffusion of adenine nucleotides through the VDAC is impeded, but the movement of PCr and Cr 
through the channel is not restricted. In the intermembrane space the phosphoryl group is transferred 
from ATP to Cr by mtCK, while formed ADP is moved back to matrix via ANT. The mitochondrial 
interactosome supercomplex enhances the transfer of energy via the CK/PCr pathway from the site of 
production to the sites of utilisation, and increases effectiveness of ATP synthesis in mitochondria  148. 
The function of mitochondrial interactosome is altered in aging 149, but it is currently unknown whether 
changes in the interactosome contribute to the mitochondrial alterations observed in obesity and T2DM. 
The observation by Scheuermann-Freestone et al. that patients with diabetes have a significantly 
impaired PCr/ATP ratio may suggest a role for the mitochondrial interactosome in the pathophysiology 
of T2DM 28.  
The discovery of mitochondrial supercomplexes and the interactosome add complexity to our 
understanding of mitochondrial physiology. While the current hypothesis suggests that the dynamic 
assembly of supercomplexes contributes to increased efficiency of electron transport and lower ROS 
production, it remains unknown in the context of obese and/or diabetic heart. As supercomplexes were 
associated with skeletal muscle adaptation to exercise, and was shown to improve skeletal muscle 
strength in sedentary humans 150, there is also reason to believe that altered assembly of these 
complexes can  contribute to the progression of heart disease.  

































































Fig.3. Mitochondrial electron transfer system – linear model (A) and assembly of supercomplexes 
(B). B left: supercomplex consisting of complex I-III-IV. B right: mitochondrial interactosome 
supercomplex consisting of ATP synthasome [comprising FoF1-ATPase, phosphate carrier (PIC), adenine 
nucleotide translocase (ANT)] and the mitochondrial creatine kinase (mtCK), voltage dependent anion 
channel (VDAC) and regulatory proteins (RP). 
3.3. Production of reactive oxygen species in obesity and T2DM 
The cellular redox environment ensures the balance between ROS production and the efficiency of ROS 
scavenging systems. When the balance is shifted towards more ROS production, and failure of the 
antioxidant systems to lower oxidative stress, cellular damage will occur. Approximately 90% of cellular 
ROS is produced in the mitochondria mainly from complexes I and III 114,151,152. Increased H2O2 resulting 
from superoxide (O2-.) production at complex I has been observed in cardiac mitochondria from obese 
mice 44,153,154. During ADP-driven respiration (coupled OXPHOS), H2O2 production was found to be higher 
in atrial tissue from patients with T2DM 107, and in obese mice with T2DM 155, compared with non-
diabetic controls. In contrast, lower ROS production was reported in high-fat-high-sugar diet fed rats 110. 
































































Whilst there are discrepancies in findings relating to ROS production, there are consistent observations 
of myocardial oxidative stress in obesity/insulin resistance 19,44,106,107,119,124 
Similarly, the up- or down-regulation of enzymatic antioxidant systems such as glutathione 
peroxidase, thioredoxin, catalase, and superoxide dismutase and the non-enzymatic antioxidant 
glutathione, have all been associated with altered mitochondrial energetics. Impaired thioredoxin-2 
signaling occurred in combination with lower mitochondrial capacity, increased ROS production and 
cardiac dysfunction in db/db mice 155 and in humans with T2DM 156. In contrast, the thioredoxin and 
catalase systems were upregulated in the hearts of other experimental obese/insulin resistance models 
110,157. It is possible that antioxidant upregulation is a compensatory mechanism to offset increased ROS 
production, however as the contribution of thioredoxin is greater when FAs are used as substrates, this 
additionally suggests a substrate-dependent effect 110. Glutathione is thought to be the major thiol 
antioxidant within cells, and lower levels of reduced glutathione or a lower reduced/oxidized glutathione 
ratio (GSH/GSSG) have been associated with mitochondrial dysfunction in humans 107, and in db/db mice 
and mice on a high-fat-high sucrose diet 153,155. Whilst supplementation of antioxidants in the context of 
heart disease has generally shown little benefit, recent evidence suggests that targeting mitochondrial 
ROS can improve energetics and maladaptation in the obese/insulin resistant heart (see section 4.4.2). 
Increased expression of mitochondrial catalase in response to high-fat diet was shown to prevent 
oxidative stress 157 and rescue diet-induced mitochondrial dysfunction 158. Furthermore, mitochondrial 
ROS scavenging was shown to improve cardiac insulin signaling and mitochondrial energetics 154. Perhaps 
focused studies to elucidate changes in redox buffering systems (i.e. thioredoxin and glutathione 
systems) in the heart associated with substrate availability and utilization could reveal origins of 
oxidative stress. Furthermore, post-translational mechanisms resulting from ROS over-production may 
also contribute to diminished redox buffering capacity in the obese and T2DM heart. 
3.4. Impaired mitochondrial calcium handling 
Mitochondrial oxidative phosphorylation is regulated by the Ca2+ concentration in the matrix. 
Accordingly, mitochondrial ATP production rate matches cardiac ATP utilization rate, independent of 
ADP feedback 159-161, by a process called excitation-energetics coupling 162. Mitochondrial Ca2+ uptake 
and extrusion occur with each excitation-contraction cycle, owing to the vicinity of mitochondria to the 
































































sarcoplasmic reticulum (SR) and their interaction through well-coordinated processes 163. Ca2+ uptake is 
mediated via the mitochondrial Ca2+ uniporter (MCU) system and occurs primarily within specialized 
microdomains between the SR and the mitochondria, where local changes in the Ca2+ concentration 
trigger opening of the MCU 164. Mitochondrial Ca2+ efflux in the heart is slower than uptake, and is 
regulated primarily by the Na+/Ca2+ exchanger (NCLX)165.   
Ca2+ accumulation in the mitochondrial matrix, which occurs during increased heart rate 163, is a key 
trigger to increase the activity of 3 important regulatory enzymes of the TCA cycle, including pyruvate, 
α-ketoglutarate and iso-citrate dehydrogenase, all of which contribute to regenerate the redox state of 
the pyridine nucleotides (NADH/NAD+ and FADH2/FAD) and enhance antioxidant capacity 166. Activation 
of the pyruvate dehydrogenase complex (PDC) also stimulates glucose oxidation, which due to the higher 
P/O ratio of glucose, contributes to cardiac efficiency at higher workloads 167. In contrast, blunted 
mitochondrial Ca2+ uptake results in the oxidation of NADH/NAD+ and FADH2/FAD and hinders the supply 
of electrons for the ETS 86,168,169. As such, Ca2+ can directly modulate the activity of the entire oxidative 
phosphorylation cascade 159-161  
Elevated intracellular Na+ in the failing heart increases NCLX-mediated Ca2+ efflux 169, and may negatively 
affect the matching of energy demand and supply. Likewise, myocardial intracellular Na+ levels are 
aggravated in diabetes, due to upregulation of the sodium-glucose co-transporter 1 (SLC5A1) 170, thus 
driving mitochondrial Ca2+ efflux through the NCLX and reducing mitochondrial calcium levels. This can 
impede key steps in the TCA cycle and in turn limit the supply of electrons to the respiratory complexes 
and lead to a shortfall in ATP synthesis 171. In the db/db mouse heart a key component of the MCU 
(MICU1) was reported to be downregulated 172, whereas targeting mitochondrial Ca2+ uptake by 
overexpression of MICU1 rescued cardiac function, lowered mitochondrial ROS, improved the NADPH 
antioxidant system, and resulted in less apoptosis mediated by oxidative stress in these diabetic hearts. 
Mice with streptozotocin-induced diabetes also exhibited reduced mitochondrial Ca2+, and restoration 
of the Ca2+ concentration by MCU overexpression in this model resulted in increased PDC activity, a shift 
in metabolism towards glucose oxidation, and improved mitochondrial membrane potential and 
respiratory efficiency 173. Recently, mitochondrial Ca2+ handling in intact cardiomyocytes from ZSF1-
obese rats, a model for diabetic cardiomyopathy, was assessed 122. At similar extracellular Ca2+ and Na+ 
































































concentrations, both cytosolic and mitochondrial Ca2+ concentrations were higher in isolated 
cardiomyocytes from diabetic animals, because of alterations in cytosolic Ca2+ handling and mild 
mitochondrial dysfunction. Furthermore, isolated mitochondria from these hearts were more prone to 
mitochondrial swelling 122, suggestive that the elevation in Ca2+ concentration made these mitochondria 
more prone to membrane permeability pore opening and apoptosis. 
Although the cause for the discrepancies in mitochondrial Ca2+ levels is not clear, we can speculate that 
differences in the severity of the disease model, multi-factorial progression of the disease, or technical 
discrepancies may be factors involved. Importantly, increased mitochondrial Ca2+ levels observed in 
cardiomyocytes from obese mice may reflect an early adaptation to the diabetic condition, whereas low 
levels of mitochondrial Ca2+ might occur as cardiomyopathy and cytosolic calcium alterations develop. 
Despite the importance of Ca2+ in modulating cardiac energy homeostasis and apoptosis, it is currently 
unclear if the SR/mitochondria interaction is altered in the diabetic heart, and whether alterations in 
mitochondrial calcium homeostasis directly influence cardiac metabolism or reflect an adaptation to 
altered energy metabolism in the T2D heart. 
4. LIFESTYLE AND PHARMACOLOGICAL INTERVENTIONS TO TARGET MITOCHONDRIAL 
METABOLISM IN THE DIABETIC HEART 
T2DM is primarily a lifestyle related disease that is progressive over time (Figure 4). Metabolic alterations 
in diabetic hearts are associated with lipotoxicity and changes in mitochondrial function. Two strategies 
might therefore be used to improve metabolism function in the diabetic heart, namely reduction of 
lipotoxicity and improvement of mitochondrial function. Alternatively altering the whole-body response 
to diabetes might indirectly improve cardiac metabolic function (Figure 4). The adoption of a healthy 
lifestyle or adoption of pharmacological interventions targeting lipotoxicity and/or mitochondrial 
function (Figure 5) are generally associated with improvements in cardiac function in T2DM. Some of 
these interventions are often also effective in reducing the age-related decline in cardiometabolic 
function in obesity and T2DM 105. Here, we focus on approaches which have a mechanistic basis involving 
modification of cardiac mitochondrial function or content.  

































































Fig.4. Aging, overnutrition, sedentary lifestyle and imbalanced circadian rhythm are risk factors for the 
development of lipotoxicity, inflammation and associat d ROS production and ion imbalance. The effect 
of these risk factors can be reduced by diet, exercise and/or pharmacological interventions, thereby 
improving insulin signaling and mitochondrial function with subsequent improvement of cardiometabolic 
function.    
 
4.1. Dietary interventions  
Several dietary interventions have led to improved health in patients or animal models with T2DM. 
Caloric restriction (CR) is one such intervention that has shown promising results, improving insulin 
sensitivity and reducing the risk of T2DM, in addition to enhancing lifespan in a wide range of animal 
models 174-179. Several studies have demonstrated that CR decreases the production of ROS and thereby 
limits oxidative damage in various tissues, including the heart 109,180,181.  This CR-induced reduction in 
ROS generation occurs without altering mitochondrial oxygen consumption in the heart 181. Since the 
lower ROS production following CR was detected in permeabilized fibres in the presence of pyruvate and 
































































malate, but not with succinate and rotenone, the source of these ROS was suggested to be mitochondrial 
complex I 181. In the Otsuka Long-Evans Tokushima Fatty rat model for T2DM, CR lowered hemoglobin 
A1c, blood glucose, cholesterol, triglycerides and circulating FAs, and lowered UCP2 expression and 
mitochondrial ROS production in the heart and aorta 182. CR for six weeks improved the metabolic 
phenotype of rats on a high-fat diet, lowering obesity, insulin resistance, and left ventricular dysfunction, 
as well as cardiac mitochondrial ROS production, membrane depolarization, and swelling 183. Of note, 
these improvements were even more pronounced when exercise was combined with CR 183.  
Signaling targets known to be activated by CR (and inhibited by a high-fat diet) include sirtuins (Sirt) 1 
and 3 174. Sirt1 is located in the nucleus, while Sirt3 is located in the mitochondria. Both are involved in 
mitochondrial function and biogenesis and the regulation of oxidative stress 184-186. The deletion of Sirt1 
expression in the heart results in a phenotype similar to diabetic cardiomyopathy and includes 
mitochondrial dysfunction in association with acetylation of PGC-1α 187,188. Furthermore, drugs causing 
dual PPARα/ϒ activation have been shown to induce cardiac dysfunction due to Sirt1-PGC1α inhibition 
and decreased mitochondrial number189.  In the hearts of fructose-fed rats, Sirt1 activity decreased early 
in the progression to T2DM and was also associated with decreased in mitochondrial content and lower 
fatty acid oxidation capacity in the mitochondria 106. Recent evidence suggests that the cardioprotective 
effect of CR in the diabetic heart operates via Sirt1 and PGC-1α, increasing OXPHOS capacity and reducing 
cardiomyocyte oxidative stress and inflammation 190. CR was also associated with an increase in Sirt3 
activity in cardiac mitochondria 191, without changes in expression level 192. The change in Sirt3 activity 
might be mediated via changes in the NAD+/NADH ratio, which decreases as a result of over-nutrition 
associated with obesity and T2DM (causing Sirt3 inactivation), and is increased by CR (causing Sirt3 
activation) 193. Sirt3 deacetylates and activates many mitochondrial enzymes including respiratory 
complexes and pyruvate dehydrogenase 193. A study using a combined in vivo and in vitro approach 
showed that the mitochondrial dysfunction and increased ROS production associated with T2DM could 
be prevented by ALDH2 activation, acting on PGC-1α function through Sirt3-mediated deacetylation194.  
One further aspect of the metabolic syndrome and T2DM that might be targeted through dietary means 
is the link between nitric oxide (NO) bioavailability, tissue metabolism and cardiovascular health. In 
humans, polymorphisms in the gene encoding endothelial NO synthase (eNOS) give rise to insulin 
































































resistance and T2DM 195,196, whilst patients with T2DM have lower myocardial eNOS protein expression 
than healthy controls 197, and a lower systemic capacity for NO synthesis198,199. Whilst the attenuated 
bioavailability of NO is commonly recognized to be a causative factor driving endothelial dysfunction, 
NO also mediates signaling effects at the cellular level through the activation of soluble guanylyl cyclase 
(sGC), increasing cyclic guanosine monophosphate (cGMP) levels and activating protein kinase G 
(PKG)200. The NO/cGMP/PKG pathway has been proposed as a possible therapeutic target in heart failure 
with preserved ejection fraction (HFpEF)200,201, and may hold promise in the specific case of diabetic 
cardiomyopathy. Of note, cGMP levels are lower in the hearts of both Zucker Diabetic Fatty rats202 and 
db/db mice203 in comparison with lean controls. In mice, eNOS deficiency results in a metabolic 
syndrome-like phenotype, including hypertension, weight gain, dyslipidemia and insulin resistance 
204,205, and in these mice the mitochondrial biogenesis response to CR is attenuated 206. Treatment with 
the phosphodiesterase 5 inhibitor tadalafil enhanced Sirt1-PGC1α signaling, thereby attenuating 
mitochondrial dysfunction in hearts of type 2 diabetic db/db mice207. More recently, restoration of the 
sGC-cGMP-PKG pathway was seen in the hearts of db/db mice following treatment with empaflagozin, 
in association with improvements in systolic and diastolic function, whilst inhibition of sGC using siRNA 
prevented these protective effects203. For more on empagliflozin see section 4.4.2. 
In addition to the endogenous route of NO synthesis 208, NO bioavailability can be increased by dietary 
supplementation with stable nitrogen oxides, e.g. nitrate (NO3-) or nitrite (NO2-) and their sequential 
reduction in vivo to NO 209. Dietary inorganic nitrate is principally acquired through the consumption of 
leafy, green vegetables and improves mitochondrial function and human health 210. Nitrate is reduced 
to nitrite via oral nitrate reductase in commensal bacteria 211. Nitrite is then converted to NO in the 
stomach by acid disproportionation 212, and is absorbed into the bloodstream. In eNOS deficient mice, 
dietary supplementation with inorganic nitrate elevated plasma and tissue levels of nitrogen oxides, and 
reversed features of the metabolic syndrome, lowering body weight, plasma triglycerides, visceral 
adiposity, fasting blood glucose, arterial blood pressure and hemoglobin A1c, whilst improving whole-
body insulin sensitivity 213. 
The link between nitrate supplementation, NO bioavailability and tissue insulin sensitivity may involve 
changes in the expression of genes involved in FAO and the control of tissue mitochondrial content. 
































































Dietary nitrate increases plasma levels of cGMP in humans 214, and enhanced FAO capacity in rat skeletal 
muscle in a mechanism that depended upon PPARα activation by cGMP 215. Additionally, mitochondrial 
biogenesis occurred with higher doses of nitrate supplementation via the activation of PGC-1α 215. 
Similarly, nitrate supplementation increased FAO capacity in rodent hearts in a PPARα-dependent 
manner 216,217. Owing to its effects on mitochondrial FAO capacity, dietary nitrate supplementation might 
be beneficial in metabolic syndrome and T2DM both systemically and to the heart in particular. This may 
be the case even when the primary cause of the metabolic condition is not deficient expression/activity 
of eNOS, and this deserves further investigation in models of T2DM beyond the eNOS knockout mouse.  
While the mechanisms behind the beneficial effects of dietary modifications on T2DM are not fully 
understood, many of the reported explanations support the involvement of cardiac mitochondria. 
Protecting the heart against mitochondrial dysfunction and oxidative stress could potentially exert 
strong effects on the development of cardiovascular defects associated with T2DM and aging. 
4.2. Interplay between circadian rhythm and myocardial function 
Whilst food quantity and quality can impact on metabolic pathways and health in T2DM, the timing of 
food intake in relation to the circadian rhythm might also deserve consideration. In the heart 
approximately 6% of protein-encoding genes show a rhythmic expression throughout the day 218, whilst 
various measures of cardiac metabolism also show diurnal variations. For example, ex vivo experiments 
on rat heart demonstrated that oxidation of exogenous glucose showed significant diurnal variation, 
whilst no such variations were seen in the oxidation of exogenous oleate 219,220. Mice that have a 
misalignment between the internal clock and the external environment (i.e. housed under a day/night 
cycle of 20 h or 30 h instead of the normal 24 h cycle) showed altered daily patterns of energy 
expenditure and carbohydrate and fat oxidation, leading to longer QT intervals 221. The metabolic 
alterations were associated with a lower cardiac mitochondrial content 222. Furthermore, expression of 
Pgc1a, Mfn1 and Opa1 was downregulated in mice with disturbed circadian rhythms, suggesting that 
the molecular clock plays a role in the regulation of cardiac mitochondrial dynamics. Of note, cardiac 
mitochondrial respiratory function appeared to be more affected in the subsarcolemmal population of 
mitochondria, in comparison with the inter-myofibrillar population 223.  
































































Time-restricted feeding has been shown to prevent and even cure diabetes in rodent models of T2DM 
(reviewed by 224) even without invoking CR 225. In nocturnal rodents, time-restricted feeding during the 
dark (i.e. active) period was associated with improved metabolic health, whilst time-restricted feeding 
during the light (i.e. inactive) period was associated with adverse metabolic outcomes 226. Rats on a time-
restricted feeding regimen have lower GSSG, protein carbonyl and malondialdehyde levels, all of which 
are indicative of substantial protection against cardiac oxidative damage in comparison with mice fed ad 
libitum 227. Data on the effects of time-restricted feeding on cardiac mitochondrial metabolism is 
somewhat scarce, but research on other tissues indicates that time-restricted feeding could impact on 
mitochondrial respiratory function. For example, livers of mice fed only during the active phase showed 
enhanced expression rhythms of mitochondrial encoding genes compared with ad libitum fed mice 228. 
The time-restricted feeding paradigm has been further studied in other model organisms. For example, 
fruit flies that were put on time-restricted feeding during their active phase showed improved cardiac 
physiology, as indicated by ex vivo heart period and arrhythmia index, together with altered cardiac gene 
expression, with circadian clock and electron transfer system (ETS) genes ranking as top clusters 229. The 
beneficial effects of time-restricted feeding on the heart are understood to be at least partly mediated 
by ATP-dependent chaperonin and mitochondrial ETS components 230. Nineteen different genes which 
encode the mitochondrial ETS were down-regulated by 10–20%, while 7 out of 8 components of an ATP-
dependent chaperonin were up-regulated in the hearts of rats on a time-restricted diet 230. 
Interestingly, the relationship between circadian rhythm and insulin signalling appears to be reciprocal, 
with several clock genes in cardiac tissue showing a phase shift in rats with a streptozotocin-induced 
diabetes 231. In the hearts of these diabetic rats, the daily rhythms of 7 molecular clock genes peaked 
about 3 hours earlier during a 24 h cycle (phase advance) compared with non-diabetic rats. 
4.3. Exercise training and cardiometabolic health  
Physical activity is associated with protection against cardiovascular disease 232, with development of the 
athletic heart characterized by normal or slightly enhanced diastolic function 233; however, the effects of 
exercise training on cardiac metabolism in humans remain somewhat unclear. In rodents, endurance 
training promotes angiogenesis 234 and decreases ROS generation 235,236 with no increase in fibrosis 237. 
Several studies have investigated the cardiometabolic effects of treadmill-running or swim-training in 
































































rodents 238. It is commonly reported that training increases myocardial FAO capacity in rodents 239-244. 
Moreover, swim-training in mice increased cardiac citrate synthase (CS) activity (a putative marker of 
mitochondrial density 245) alongside increased PGC-1α expression 244. Of note, moderate intensity 
training (MIT) elicited different effects to high intensity interval training (HIIT) in mice when treadmill-
running at matched distances 246,247. Whilst both regimens increased skeletal muscle CS activity, only 
HIIT resulted in increased cardiac CS, alongside increased mitochondrial respiratory capacity and 
improved cardiac efficiency (work/O2 consumed) 246.  
The metabolic effects of endurance training are likely to benefit the obese/diabetic heart, through 
improvements in substrate metabolism, lipid handling, mitochondrial function and antioxidant capacity 
248. Indeed in mice with diet-induced obesity, both MIT and HIIT prevented concentric left ventricle 
remodelling and improved systolic and diastolic function, whilst lowering fibrosis and oxidative stress 19. 
Moreover, both exercise modalities were associated with changes in myocardial substrate utilisation 
with increased work-adjusted rates of glucose oxidation and decreased work-adjusted rates of palmitate 
oxidation in isolated, perfused hearts from diet-induced obese mice, suggesting a partial restoration in 
substrate balance towards that of non-obese mice 19. The authors further reported a normalisation of 
mitochondrial respiratory function in the diet-induced obese heart following HIIT, with increased 
OXPHOS capacity and improved efficiency (higher P/O ratios) in isolated cardiac mitochondria supplied 
with glutamate and malate as substrates for the N-Pathway via Complex I 19. Similarly, both in rats fed 
an obesogenic high-fat, high-sucrose diet for 12 weeks and controls on a non-obesogenic diet, HIIT 
enhanced mitochondrial oxygen consumption rates supported by palmitoylcarnitine and malate, 
suggesting enhanced FAO capacity following training 110. HIIT was also found to elicit cardioprotective 
effects in high-fat fed mice, with decreased infarct sizes following myocardial ischemia alongside lower 
work-independent oxygen consumption and lower ROS production in comparison with sedentary 
controls, suggesting at least a partial normalisation of mitochondrial function in these hearts 249.  
Studies in the overtly diabetic db/db mouse have also suggested beneficial effects of training on cardiac 
mitochondrial function. For instance, 15 weeks of endurance training lowered fibrosis and enhanced 
mitochondrial content in db/db mice (7 weeks of age at the start of the training protocol), with increased 
expression of a number of mtDNA-encoded genes 250. Mechanistically, this was attributed to exercise-
induced activation of Akt and PGC-1α signaling, which was otherwise inhibited in the diabetic heart 250. 
































































Similarly, in a separate study 5 weeks of MIT on a treadmill lowered fibrosis and improved ATP levels in 
the hearts of db/db mice at 4 months of age, alongside improved oxygen consumption rates and 
improved contractile function in isolated cardiomyocytes 251. In addition to effects on mitochondrial 
content and respiratory capacity, exercise may also influence mitochondrial dynamics, with decreased 
expression of DRP1 relative to that of the mitochondrial fusion factor Mfn1 seen following exercise in 
db/db mice 251. The protective effects of exercise may be more limited in the older diabetic heart, 
however. In 8 month old db/db mice, three weeks of endurance training resulted in increased myocardial 
expression of PGC-1α alongside increased mtDNA density, but decreased ETS complex expression and 
increased mitochondrial fission, which the authors attributed to increased oxidative stress following 
exercise in older diabetic hearts 252.   
Beyond direct effects on the myocardium, endurance training is likely to have further beneficial 
effects for the metabolically-diseased heart. Skeletal muscle is the largest insulin-sensitive tissue in the 
body, and improvements in muscle mitochondrial function and FAO capacity via training may prevent 
accumulation of lipotoxic intermediates associated with insulin resistance improving whole-body 
glycemic control 253,254.  Moreover, weight loss is itself associated with improved myocardial energetics 
and diastolic function 255 and may result from a sustained increase in physical activity.  
 
4.4. Pharmacologic targeting of mitochondria in insulin resistance.  
4.4.1. Compounds to reduce lipotoxicity 
The accumulation of lipid intermediates advances myocardial insulin resistance, therefore targeting 
this lipid overload is a possible strategy to improve insulin sensitivity and mitochondrial function in the 
diabetic heart. Several treatment approaches have been trialled in animal models and clinical settings, 
however for various reasons, use of mitochondria-protective metabolic modulators against lipid 
overload is currently limited in clinical practice. The main targets for preventing accumulation of FAO 
intermediates are related to long-chain acylcarnitines (Figure 5). These include the pharmacological 
reduction of CPT1 activity by using direct or indirect inhibitors of CPT1 and the use of carnitine-lowering 
compounds. 
































































Direct inhibitors of CPT1 (etomoxir, perhexiline, oxfenicine, teglicar) have been shown to decrease 
long-chain acylcarnitine concentration, inhibit FAO (at least partially), and increase glucose oxidation in 
heart 256-259. It has been shown that etomoxir and perhexiline improve cardiac function in patients with 
heart failure or cardiomyopathy 260-262. A fall in long-chain acylcarnitines following CPT1-inhibition 
improved insulin sensitivity in experimental models of insulin resistance 263,264, however, CPT1 inhibitors 
are not currently prescribed due to hepatotoxic and cardiotoxic effects 262,265 which may relate to 
unspecific side effects in mitochondria 266. An alternative approach is to increase the concentration of 
malonyl-CoA, an endogenous CPT1 inhibitor, using malonyl-CoA decarboxylase (MCD) inhibitors (e.g. 
CBM-301106, CBM-301940). MCD inhibition decreases long-chain acylcarnitines and FAO, thereby 
promoting glucose oxidation and improving insulin sensitivity 267-269. Studies in animal models have 
suggested that MCD is a possible drug target for the treatment of diabetic cardiomyopathy, however, 
further studies are necessary to prove the therapeutic efficacy of pharmacological inhibition of MCD. 
Treatment with inhibitors of carnitine biosynthesis and its transport into tissues (e.g. with the 
clinically prescribed drug meldonium (3-(2,2,2-trimethylhydraziniumyl) propionate) or experimental 
candidate methyl-GBB (4-[ethyl(dimethyl)ammonio]butanoate), is protective against cardiometabolic 
disease 70,270-276. These two compounds decrease long-chain acylcarnitine content in cardiac tissues and 
mitochondria and therefore prevent acylcarnitine-induced mitochondrial damage as well as impaired 
insulin signalling. Both compounds protect cardiac mitochondria against ischemia-reperfusion injury 
272,277,278, reduce infarct size in healthy and diabetic animals, and improve insulin sensitivity in 
experimental models of insulin resistance 70,273,279.  
Trimetazidine and ranolazine are clinically used as antianginal agents. Growing evidence suggests 
that trimetazidine treatment can reduce the severity of adverse cardiovascular events in both 
experimental models of insulin resistance and in patients with T2DM 280-282. It was first proposed that 
trimetazidine inhibits FA metabolism in cardiac mitochondria by inhibiting long-chain 3-ketoacyl CoA 
thiolase (the last enzyme in the β-oxidation pathway). More recently, however, it has been 
demonstrated that trimetazidine does not alter metabolic substrate oxidation in the cardiac 
mitochondria of T2DM patients 283,284. The antianginal effects of ranolazine are achieved by blocking the 
late sodium channels, thereby preventing a downstream rise in cytosolic Ca2+ concentrations285. In 
































































addition, ranolazine may be useful in the management of stable ischemic heart disease with diabetes, 
as indicated by a fall in circulating hemoglobin A1c 286,287. 
4.4.2. Improving mitochondrial function 
Whilst the targeting of mitochondria is not a novel approach for the treatment of metabolic 
disorders or cardiovascular disease, studies of the efficacy of mitochondria-targeted compounds in the 
diabetic heart are somewhat limited (Figure 5). One such strategy might include treatment with 
mitochondrial-targeted antioxidants, such as MitoQ and MitoTEMPO. These compounds comprise a 
lipophilic cation (Tetraphenylphosphonium [TPP]) conjugated to an anti‐oxidant component.    
MitoQ treatment has been shown to decrease H2O2 formation and improve mitochondrial 
respiratory capacity in the heart following ischemia-reperfusion 288 and in pressure overload-induced 
heart failure 289. In experimental models of diabetes, MitoQ treatment reduced diabetic nephropathy by 
ameliorating mitophagy and the production of excess ROS290,291 and modulated oxidative stress in 
leucocytes isolated from T2DM patients292. The efficacy of MitoQ has not, however, been assessed in 
the diabetic heart.   
MitoTEMPO prevents mitochondrial permeability transition pore opening, necrosis and 
mitochondrial apoptosis after ATP depletion293,294. Treatment of hyperglycemic and/or hyperinsulinemic 
animals with MitoTEMPO improved cardiac function295-297. Moreover, enhanced mitochondrial 
antioxidant capacity following MitoTEMPO treatment improved insulin sensitivity and preserved 
cardiovascular function in animals with metabolic syndrome or diabetes, as well as in aged animals298-
300. Analysis of ROS-sensitive networks, particularly those associated with MitoTEMPO treatment, 
highlighted that increased mitochondrial ROS in the metabolically-diseased heart disrupts the normal 
coupling between cytosolic signals and nuclear gene programs underpinning mitochondrial respiratory 
function, antioxidant capacity, Ca2+ handling and action potential repolarization 301-304.  
Resveratrol, a natural polyphenol, is a multi-target compound and has been widely studied in the 
context of diabetes305. In addition to its anti-oxidant properties, treatment with resveratrol improves 
mitochondrial OXPHOS and biogenesis by activating Sirt1 and Sirt3 in experimental models of insulin 
resistance 187,306.  Although treatment with resveratrol has shown promising results in preclinical studies 
































































307-309, no effect of resveratrol was observed on different markers of cardiovascular disease risk in aging 
and obese individuals 310. Recent studies have demonstrated that resveratrol supplementation improves 
skeletal muscle mitochondrial function, however it does not improve insulin sensitivity in people at risk 
of or with T2DM 311,312. Further studies aiming to understand resveratrol metabolism and 
pharmacokinetics, may therefore be required to realise the therapeutic potential of this approach. 
Elamipretide (SS-31) is a mitochondrial-targeted tetrapeptide that interacts with cardiolipin. It has 
been proposed that elamipretide stabilizes cardiolipin, thereby reducing ROS production and preserving 
ETS function under stressed conditions 313-315, and might improve supercomplex stability. Elamipretide 
improved calcium retention capacity in cardiac mitochondria, and reduced infarct size in the hearts of 
STZ-treated rats 316.  Moreover elamipretide improved mitochondrial organization and attenuated 
oxidative stress in a swine model of metabolic syndrome 317. 
One group of drugs that has received significant attention in recent years are inhibitors of the renal 
sodium-glucose cotransporter (SGLT2) 169. High-capacity, low-affinity SGLT2 are located in the renal 
proximal tubular epithelium and reabsorb filtered glucose. SGLT2 inhibitors lower blood sugar, and have 
been associated with loss of body weight in patients with T2D, attributable to the induction of a negative 
caloric balance 318. In addition, it is suggested that SGLT2 inhibition promotes production of ketone 
bodies, which can act as an efficient substrate for myocardial energy production319. One such compound, 
empagliflozin, has been shown to improve cardiac outcome and reduce mortality in diabetic patients 320-
322. The mechanism by which empagliflozin improves cardiac outcome is a matter of current debate, 
although improved cytosolic and mitochondrial Ca2+ and sodium homeostasis has been suggested to play 
a role 169. Cardioprotection in rats with metabolic syndrome following treatment with dapagliflozin, 
another SGLT2 inhibitor was associated with changes in fusion/fission proteins towards control values, 
as well as lower cellular ROS production 323.  

































































Fig. 5. Pharmacologic targeting of mitochondria in insulin resistant heart. The main strategies are 
reduction/prevention of accumulation of long-chain (LC) acylcarnitines (direct and indirect inhibitors of 
CPT1) and targeting mitochondria functionality. Mitochondria targeting may include reduction of ROS 
(mitochondrial-targeted antioxidants), improving OXPHOS and biogenesis (resveratrol), stabilization of 
supercomplexes by preservation of membrane lipid composition (elamipretide), and improvement of 
cytosolic and mitochondrial Ca2+ homeostasis (SGLT2 inhibitors).  
 
5. CONCLUDING REMARKS 
The alterations in metabolism in insulin-resistant and T2DM hearts can be studied at various levels, 
from long-term treatment of cultured cells with high concentrations of glucose, through to studies of 
the whole heart or at the whole body level in diabetic animal or human subjects. Many of the findings 
discussed in this review were derived from human or animal studies, and arguably the pathophysiology 
































































of diabetic cardiomyopathy is best understood by studying the interactions between various 
contributing factors in humans.  
Human studies are intrinsically limited, however, in part due to the practical difficulties and ethical 
implications associated with obtaining cardiac tissue from living patients, but also owing to uncertainties 
about the time course of the disease and the difficulty of inferring cause vs effect in observational 
studies. Moreover, most patients with T2DM are over 50 years old, and suffer from co-morbidities, such 
as obesity, hypertension, atherosclerosis or inactivity-related metabolic alterations. As such, studying 
T2DM in animal models has proven to be valuable for our understanding of the pathophysiology of 
diabetic cardiomyopathy. The choice of animal model varies depending on the specific research 
question, cost and ease-of-use (see 324 for an overview of animal models). The time course of disease 
and nature of the T2DM model (genetic, diet-induced or diet plus streptozotocin-induced) can influence 
the severity of metabolic and mitochondrial alterations, as well as the progression of cardiac dysfunction, 
and might explain discrepancies between findings across different studies. Co-morbidities are often 
overlooked in studies using rodents, complicating the translation of results to the human setting. Future 
work is therefore needed to understand the interplay between factors such as age, inactivity and cardiac 
mitochondrial dysfunction in T2DM. New animal models with a slower disease progression, such as the 
Nile rat 325-327, could play an important role in understanding the role of cardiac mitochondrial 
dysfunction in T2DM.  
Regardless of whether the altered mitochondrial metabolism observed in the diabetic heart is a 
cause or a consequence of myocardial insulin resistance, the mitochondria are central to the 
maintenance of cardiac metabolism and contractile function. Thus, targeting mitochondrial function to 
delay or reverse diabetic cardiomyopathy is an attractive, but underexplored avenue for future 
treatment options. Reducing mitochondrial lipotoxicity and oxidative stress seem effective in 
experimental animal models, but such strategies have not yet been translated to the clinic. On the other 
hand, the promising effects of treatment with the renal SGLT2 inhibitor empagliflozin may include a 
cardiac mitochondrial component 169. Likewise, nutritional interventions and physical exercise both have 
proven benefits for the contractile function of the heart, at least in part due to improved cardiac 
































































mitochondrial function. However, to what extent these effects occur through improvements in whole-
body insulin sensitivity vs heart metabolic function in particular remain to be determined.  
 In conclusion, we have highlighted how T2DM alters glucose and FA oxidation and can lead to 
FA-induced lipotoxicity and mitochondrial dysfunction. The alterations observed in mitochondrial 
substrate utilization, bioenergetic function and fission/fusion indicate that mitochondrial function is 
significantly altered in T2DM. Future work needs to focus on the regulation of FA metabolism, the 
dynamic assembly/organization of the ETS complexes and the regulation of fusion/fission in obesity and 
diabetes, as well as the role of circulating inflammatory markers in response to physiological changes. 
Finally, the improvement of metabolic and mitochondrial function through lifestyle (nutrition and 
exercise) and pharmacological interventions could be an important strategy to improve cardiovascular 
performance in diabetes.  
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